Drug Approval | October 21, 2024
Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Subscribe To Our Newsletter & Stay Updated
